JP2016540729A5 - - Google Patents

Download PDF

Info

Publication number
JP2016540729A5
JP2016540729A5 JP2016522037A JP2016522037A JP2016540729A5 JP 2016540729 A5 JP2016540729 A5 JP 2016540729A5 JP 2016522037 A JP2016522037 A JP 2016522037A JP 2016522037 A JP2016522037 A JP 2016522037A JP 2016540729 A5 JP2016540729 A5 JP 2016540729A5
Authority
JP
Japan
Prior art keywords
kgp
subject
snp
glatiramer acetate
genotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016522037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540729A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/061647 external-priority patent/WO2015061367A1/en
Publication of JP2016540729A publication Critical patent/JP2016540729A/ja
Publication of JP2016540729A5 publication Critical patent/JP2016540729A5/ja
Withdrawn legal-status Critical Current

Links

JP2016522037A 2013-10-21 2014-10-21 酢酸グラチラマーへの応答を予測する遺伝子マーカー Withdrawn JP2016540729A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361893807P 2013-10-21 2013-10-21
US61/893,807 2013-10-21
US201462048127P 2014-09-09 2014-09-09
US62/048,127 2014-09-09
US201462048641P 2014-09-10 2014-09-10
US62/048,641 2014-09-10
PCT/US2014/061647 WO2015061367A1 (en) 2013-10-21 2014-10-21 Genetic markers predictive of response to glatiramer acetate

Publications (2)

Publication Number Publication Date
JP2016540729A JP2016540729A (ja) 2016-12-28
JP2016540729A5 true JP2016540729A5 (https=) 2017-11-30

Family

ID=52826364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016522037A Withdrawn JP2016540729A (ja) 2013-10-21 2014-10-21 酢酸グラチラマーへの応答を予測する遺伝子マーカー

Country Status (13)

Country Link
US (2) US9702007B2 (https=)
EP (1) EP3060681A4 (https=)
JP (1) JP2016540729A (https=)
KR (1) KR20160098199A (https=)
CN (1) CN105658818A (https=)
AU (1) AU2014340247A1 (https=)
CA (1) CA2926724A1 (https=)
EA (1) EA201690759A1 (https=)
IL (1) IL244783A0 (https=)
MX (1) MX2016005003A (https=)
TW (1) TW201610166A (https=)
UY (1) UY35790A (https=)
WO (1) WO2015061367A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
NZ703122A (en) 2010-10-11 2016-06-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
MX2015004563A (es) 2012-10-10 2015-07-14 Teva Pharma Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HUE071047T2 (hu) 2016-08-31 2025-07-28 Mapi Pharma Ltd Glatiramer-acetátot tartalmazó depórendszerek
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
DK3820573T3 (da) 2018-07-10 2023-10-23 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
CN111088368B (zh) * 2019-12-30 2021-04-16 山西医科大学 一种血液mRNA检测试剂盒及检测方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
SI1115743T1 (sl) 1998-09-25 2010-01-29 Yeda Res And Dev Co Ltd The We Polipeptidi, sorodni kopolimeru 1, za uporabo kot markerji molekulske mase in za terapevtsko uporabo
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU6281599A (en) 1998-10-02 2000-04-26 Yeda Research And Development Co. Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
CA2355400A1 (en) 1998-11-12 2000-05-18 Yeda Research And Development Co., Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
WO2001060392A1 (en) 2000-02-18 2001-08-23 Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science Oral, nasal and pulmonary dosage formualtions of copolymer 1
CA2411536A1 (en) 2000-06-05 2001-12-13 V. Wee Yong The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
SI1459065T1 (sl) 2001-12-04 2010-11-30 Teva Pharma Postopki za merjenje potentnosti glatiramer acetata
NZ569331A (en) 2003-01-21 2010-08-27 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
EP1603530A1 (en) 2003-03-04 2005-12-14 Teva Pharmaceutical Industries Limited Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
PT1638589E (pt) 2003-05-14 2014-06-12 Teva Pharma Terapia combinada com acetato de glatirâmero e mitoxantrona para o tratamento da esclerose múltipla
US20050064483A1 (en) 2003-08-28 2005-03-24 Baylor College Of Medicine Gene expression profiling technology for treatment evaluation of multiple sclerosis
US20050170004A1 (en) 2003-10-31 2005-08-04 Vered Rosenberger Nanoparticles for drug delivery
AU2005218625A1 (en) 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
CA2571035A1 (en) 2004-06-25 2006-01-12 Id Biomedical Corporation Of Quebec Compositions and methods for treating neurological disorders
US20090048181A1 (en) 2004-09-02 2009-02-19 Schipper Hyman M Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
US7495072B2 (en) 2004-09-09 2009-02-24 Teva Pharmaceutical Industries, Ltd. Process for preparation of mixtures of polypeptides using purified hydrobromic acid
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
KR20070108388A (ko) 2005-02-02 2007-11-09 테바 파마슈티컬 인더스트리즈 리미티드 가수소분해를 이용한 폴리펩타이드의 혼합물의 제조방법
PL1848415T3 (pl) 2005-02-17 2013-10-31 Teva Pharma Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
US20100167983A1 (en) 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
WO2006116602A2 (en) 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007030573A2 (en) 2005-09-09 2007-03-15 Yeda Research And Development Co. Ltd. Polypeptides useful for molecular weight determinations
WO2007081975A2 (en) 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20080118553A1 (en) 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US20090149541A1 (en) 2007-11-28 2009-06-11 Yafit Stark Method of delaying the onset of clinically definite multiple sclerosis
CN102176900B (zh) * 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
EP2406396A2 (en) * 2009-03-12 2012-01-18 Brainco Biopharma, S.L. A genotyping tool for improving the prognostic and clinical management of ms patients
NZ577731A (en) * 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
RS52367B (sr) 2009-07-15 2012-12-31 Teva Pharmaceutical Industries Ltd. Formulacije glatiramer acetata smanjene zapremine i postupci primene
ES2612001T4 (es) * 2009-08-20 2018-02-07 Yeda Research & Development Company, Ltd. Terapia de baja frecuencia con acetato de glatirámero
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ703122A (en) 2010-10-11 2016-06-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
EP2728646B1 (en) * 2011-07-01 2016-05-18 Zeon Corporation Membrane poreuse pour batteries secondaires, procédé de sa fabrication et utilisation de celle-ci
KR20140101730A (ko) * 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
MX2015004563A (es) 2012-10-10 2015-07-14 Teva Pharma Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
JP2016503803A (ja) 2012-12-21 2016-02-08 テバ ファーマシューティカル インダストリーズ リミティド 酢酸グラチラマーの経粘膜送達
CA2895457A1 (en) 2012-12-21 2014-06-26 Teva Pharmaceutical Industries Ltd. Oral transmucosal delivery of glatiramer acetate
JP2016504039A (ja) 2013-01-04 2016-02-12 テバ ファーマシューティカル インダストリーズ リミティド グラチラマーアセテート関連医薬品の特性決定
MX2015012156A (es) 2013-03-12 2015-11-30 Teva Pharma Terapia de induccion de rituximab seguida por terapia de acetato de glatiramer.
CN103169670B (zh) * 2013-03-22 2016-07-06 深圳翰宇药业股份有限公司 一种醋酸格拉替雷微球及其制备方法
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product

Similar Documents

Publication Publication Date Title
JP2016540729A5 (https=)
TW201326399A (zh) 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
US20050165115A1 (en) Methods and compositions for predicting compliance with an antidepressant treatment regimen
AU2012229333B2 (en) Methods and materials for assessing responsiveness to lenalidomide, thalidomide, and/or other thalidomide analogs
US9702007B2 (en) Genetic markers predictive of response to glatiramer acetate
JP2014530819A5 (https=)
Tang et al. Role of gene polymorphisms/haplotypes and serum levels of interleukin-17A in susceptibility to viral myocarditis
De Castro et al. Genetic variants of the DDR1 gene are associated with vitiligo in two independent Brazilian population samples
JP5899527B2 (ja) 第６染色体短腕２１．３３領域の一塩基多型に基づく抗てんかん薬による薬疹リスクの検査方法
JP2019533987A5 (https=)
Dickerson et al. Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia
WO2010111080A2 (en) Optimized treatment of schizophrenia
Verpillat et al. Use of haplotype information to test involvement of the LRP gene in Alzheimer's disease in the French population
CN102732616A (zh) 检测CDH23基因c.403C>T突变的试剂盒
TW201701897A (zh) 選擇對醋酸格拉替雷（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之反應具預測性之單一核苷酸多型性
CN102787163B (zh) 检测OTOF基因c.1671_1673delG突变的试剂盒
CN102851359A (zh) 检测SLC26A4基因c.665G＞T突变的试剂盒
JP2016202135A (ja) チオプリン製剤による副作用の危険性の判定方法
JP6474198B2 (ja) 内臓脂肪蓄積感受性の判定方法
EP1853909A2 (en) Genetic markers in the csf2rb gene associated with an adverse hematological response to drugs
CN102732613A (zh) 检测OTOF基因c.5833delG突变的试剂盒
CN102732615A (zh) 检测OTOF基因c.2382_2383delC突变的试剂盒
US20220259656A1 (en) Blood biomarker and genetic markers associated with response to crth2 receptor antagonists
Mohammad et al. Prevalence of calreticulin exon 9 mutation in Iranian population with cardiovascular disease
CN101805784B (zh) 人wnk4基因的单核苷酸多态性及其用途